AbbVie (ABBV) Aperçu de l'action
AbbVie Inc. est une société biopharmaceutique de recherche qui se consacre à la recherche et au développement, à la fabrication, à la commercialisation et à la vente de médicaments et de thérapies dans le monde entier. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 2/6 |
| Croissance future | 4/6 |
| Performances passées | 0/6 |
| Santé financière | 2/6 |
| Dividendes | 4/6 |
Récompenses
Analyse des risques
ABBV Community Fair Values
Create NarrativeSee what 449 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbbVie Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$248.08 |
| Plus haut sur 52 semaines | US$261.64 |
| Plus bas sur 52 semaines | US$184.63 |
| Bêta | 0.28 |
| Variation sur 1 mois | 10.28% |
| Variation sur 3 mois | 19.30% |
| Variation sur 1 an | 28.91% |
| Variation sur 3 ans | 82.40% |
| Variation sur 5 ans | 111.13% |
| Évolution depuis l'introduction en bourse | 608.80% |
Nouvelles et mises à jour récentes
Recent updates
ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline
Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.AbbVie: Immunology Cash Flow Funds Oncology Expansion
Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking AlphaAbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update
AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution
AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings
The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution
Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution
Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns
Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty
The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality
Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty
Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality
Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution
Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution
Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution
Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections
AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73
The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures
AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025
AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.Expanding Immunology And Neuroscience Will Reshape Global Healthcare
AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.Rendement pour les actionnaires
| ABBV | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | -5.0% | 0.02% | 0.6% |
| 1Y | 28.9% | 36.1% | 19.5% |
Rendement vs Industrie: ABBV a sous-performé le secteur US Biotechs qui a rapporté 36.1 % au cours de l'année écoulée.
Rendement vs marché: ABBV a dépassé le marché US qui a rapporté 19.5 % au cours de l'année écoulée.
Volatilité des prix
| ABBV volatility | |
|---|---|
| ABBV Average Weekly Movement | 4.1% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Cours de l'action stable: ABBV n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de ABBV ( 4% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2012 | 57,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. est une société biopharmaceutique de recherche qui se consacre à la recherche et au développement, à la fabrication, à la commercialisation et à la vente de médicaments et de thérapies dans le monde entier. L'entreprise propose Skyrizi pour traiter les maladies auto-immunes ; Rinvoq pour traiter les maladies inflammatoires ; Imbruvica pour le traitement des patients adultes atteints de cancers du sang ; Venclexta pour traiter les cancers du sang ; Elahere pour traiter divers cancers ; Epkinly pour traiter les lymphomes ; et Emrelis pour le traitement du cancer du poumon. Elle propose également des produits injectables pour le visage, des produits de médecine plastique et régénérative, des produits de remodelage du corps et des produits de soins de la peau ; botox Cosmetic pour le traitement des rides glabellaires, des pattes d'oie, des rides du front et des bandes platysma ; Juvederm Collection pour traiter la perte de volume au niveau des tempes, des paupières inférieures, des joues, du menton, des lèvres et de la partie inférieure du visage ; En outre, la société propose Ozurdex pour la déficience visuelle, Lumigan/Ganfort et Alphagan/Combigan pour la réduction de la pression intraoculaire élevée chez les patients atteints de glaucome à angle ouvert ou d'hypertension oculaire, ainsi que d'autres produits de soins oculaires, notamment Refresh/Optive, Xen, Durysta et Restasis.
AbbVie Inc. Résumé des fondamentaux
| ABBV statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$441.54b |
| Bénéfices(TTM) | US$3.60b |
| Recettes(TTM) | US$62.82b |
Le site ABBV est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| ABBV compte de résultat (TTM) | |
|---|---|
| Recettes | US$62.82b |
| Coût des recettes | US$17.57b |
| Marge brute | US$45.25b |
| Autres dépenses | US$41.65b |
| Les revenus | US$3.60b |
Derniers bénéfices déclarés
Mar 31, 2026
Prochaine date de publication des résultats
Jul 31, 2026
| Résultat par action (EPS) | 2.03 |
| Marge brute | 72.03% |
| Marge bénéficiaire nette | 5.72% |
| Ratio dettes/capitaux propres | -1,102.7% |
Quelles ont été les performances à long terme de ABBV?
Voir les performances historiques et les comparaisonsDividendes
Le site ABBV verse-t-il des dividendes fiables ?
Voir ABBV l'historique des dividendes et les indices de référence| AbbVie dates des dividendes | |
|---|---|
| Date ex-dividende | Jul 15 2026 |
| Date de paiement du dividende | Aug 14 2026 |
| Jours jusqu'au dividende Ex | 4 days |
| Jours jusqu'à la date de paiement du dividende | 34 days |
Le site ABBV verse-t-il des dividendes fiables ?
Voir ABBV l'historique des dividendes et les indices de référenceAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/10 21:55 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
AbbVie Inc. est couverte par 51 analystes. 24 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| David Toung | Argus Research Company |
| Emily Field | Barclays |
| Luisa Hector | Berenberg |